Modulation of dopaminergic neurotransmission in the 6-hydroxydopamine lesioned rotational model by peptidomimetic analogues of L-prolyl-L-leucyl-glycinamide

Brain Research

Volumn 737, Issue 1-2, 1996, Pages 287-291

  Ott, Michael C ^a   Mishra, Ram K ^a   Johnson, Rodney L ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

6 Hydroxydopamine lesion; Apomorphine; MIF 1; PLG analog; Prolyl leocyl glycinamide; Striatal dopamine receptor

Indexed keywords

APOMORPHINE; DOPAMINE RECEPTOR; NEUROPEPTIDE; OXIDOPAMINE; PROLYLLEUCYLGLYCINAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; TARDIVE DYSKINESIA;

EID: 0030597196     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(96)00927-4     Document Type: Article

References (26)

1. 3 apomorphine binding sites, Gen. Pharmacol., 14 (1983) 609-614.
2. [2] Barbeau, A., Potentiation of levadopa effect by intravenous L-propyl-L-leucyl-glycinamide in man, Lancet, 2 (1975) 683-684.
3. [3] Barbeau, A., Roy, M., Gonce, M. and Labreoque, L., Newer therapeutic approaches in Parkinson's disease. In L.J. Poirtier and T.L. Sourkes (Eds.) ,Advances in Neurology, Raven Press, New York, 1978, pp. 433-437.
4. [4] Barbeau, A., Roy, M. and Kastin, A.J., Double blind evaluation of oral L-prolyl-L-leucyl-glycine amide in Parkinson's disease. Can. Med. Assoc. J., 114 (1976) 120-122.
5. [5] Bhargava, H.N., Effects of prolyl-leucyl-glycinamide and cyclo(leucyl-glycine) on the supersensitivity of dopamine receptors in the brain induced by chronic administration of haloperidol to rats, Neuropharmacology, 23 (1984) 439-444.
6. [6] Celis, M.E., Taleisnik, S. and Walter, R., Regulation of formation and proposed structure of the factor inhibiting the release of alpha-MSH, Proc. Natl. Acad. Sci., 68 (1971) 1428-1433.
7. [7] Chiu, S., Paulose, C.S. and Mishra, R.K., Effects of L-prolyl-L-leucyl-glycinamide (PLG) on neuroleptic-induced catalepsy and dopamine/neuroleptic receptor bindings, Peptides, 2 (1981) 105-111.
8. [8] Chiu, S., Paulose, C.S. and Mishra, R.K., Neuroleptic drug-induced dopamine receptor supersensitivity: antagonism by L-prolyl-L-leucyl glycinamide, Science, 214 (1981) 1261-1262.
9. [9] Ehrensing, R.H. and Kastin, A.J., Dose related bi-phasic effects of propyl-leucyl-glycinamide (MIF-1) in depression, Am. J. Psychiatry, 135 (1978) 562-566.
10. [10] Ehrensing, R.H., Kastin, A.J., Wurzlow, G.F., Michell, G.F. and Mebane, A.H., Improvement in major depression after low subcutaneous doses of MIF-1, J. Affect. Dis., 31 (1994) 227-233.
11. [11] Hara, C. and Kastin, A.J. Biphasic effects of MIF-1 and tyr-MIF-1 on apomorphine-induced stereotypy in rats, Pharmacol. Biochem. Behav., 25 (1986) 757-761.
12. [12] Hatta, K., Wolterink, G. and Van Ree, J.M., Prolyl-leucyl-glycinamide, thyrotropin releasing hormone and β-endorphin-(10-16), like antidepressants, antagonize melatonin-induced behaviourial changes in rats. Eur. J. Pharmacol., 284 (1995) 327-330.
13. [13] Heikkila, R.E., Shapiro, B.S. and Duvoisin, R.C., The relationship between loss of dopamine nerve terminals, striatal H3-spiroperidol binding and rotational behavior in unilaterally 6-hydroxydopamine lesioned rats, Brain Res., 211 (1981) 285-292.
14. [14] Hudson, J.L., van Horne, C.G., Stromberg, I., Brock, S., Clayton, J., Masserano, J., Hoffer, B.J. and Gerhardt, G.A., Correlation of apomorphine and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats, Brain Res., 626 (1993) 167-174.
15. [15] Johnson, R.L., Rajakumar, G., Yu, K.L. and Mishra, R.K., Synthesis of pro-leu-gly-NH2 analogues modified at the propyl residue and evaluation of their effects on the receptor binding activity of the central dopamine receptor agonist, J. Med Chem., 29 (1986) 2104-2107.
16. [16] Kastin, A.J. and Barbeau, A., Preliminary clinical trials with MIF in Parkinson's disease, Can. Med. Assoc. J., 107 (1972) 1079-1081.
17. [17] Kostrzewa, R.M., Dopamine receptor supersensitivity. Neurosci. Biobehav. Rev., 19 (1995) 1-17.
18. [18] Kostrzewa, R.M., Kastin, A.J. and Sobrain, S.K., Potentiation of apomorphine action in rats by L-prolyl-L-leucyl-glycinamide, Pharmacol. Biochem. Behav., 9 (1978) 375-378.
19. [19] Mishra, R.K., Chiu, S., Chiu, P. and Mishra, C.P., Pharmacology of L-propyl-L-leucyl-glycinamide (PLG): a review. Methods Find. Exp. Clin. Pharmacol., 5 (1983) 203-233.
20. [20] Mishra, R.K., Chiu, S., Singh, A.N., Kazmi, S.M.I., Rajakumar. G. and Johnson, R.L., L-Prolyl-L-Leucyl-Glycinamide (PLG) and it's analogs: clinical implications in extrapyramidal motor disorders and depression. Correl. Pharmacostruct., 11 (1986) 203-207.
21. [21] Paxinos, G. and Watson, C., The Rat Brain in Stereotaxic Coordinates, Academic Press, Toronto, 1986.
22. [22] Pliska, V., Models to explain dose response relationships that exhibit a down turn phase, Trends Pharmacol. Sci. 15 (1994) 178-181.
23. [23] Quoek, R.M., Lucas, T.S. and Hartl, T.J., Potentiation of apomorphine-induced sterotypics by naloxone and L-propyl-L-leucyl-glycinamide, Pharmacol. Biochem. Behav., 19 (1983) 40-52.
24. [24] Rajakumar, G., Naas, F., Johnson, R.L., Chiu, S., Yu, K.L. and Mishra, R.K., Down regulation of haloperidol-induced striatal dopamine receptor supersensitivity by active analogues of L-prolyl-L-leucyl-glycinamide (PLG), Peptides, 8 (1987) 855-861.
25. [25] Smith, J.R. and Morgan, M., Effect of PLG on drug induced rotation in rats, Gen. Pharmacol., 13 (1982) 203-207.
26. [26] Srivastava, L.K., Bajwa, S.B., Johnson, R.L. and Mishra, R.K., Interaction of L-Prolyl-L-Leucyl Glycinamide with dopamine D2 receptor; evidence for modulation of agonist affinity states in bovine striatal membranes, J. Neurochem., 50 (1988) 960-968.